Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis (AKTSS)

To see complete record on, please visit this link

Id: NCT03296345

Organisation Name: UCSF Benioff Children's Hospital Oakland

Overal Status: Completed

Start Date: June 2016

Last Update: April 20, 2021

Lead Sponsor: UCSF Benioff Children's Hospital Oakland

Brief Summary: Acute vaso-occlusive episodes (VOEs) in sickle cell disease (SCD) are primarily managed with opioids. Tolerance and hyperalgesia to opioids develops due to N-methyl-D-aspartate (NMDA)-receptor mediated activation of the nociceptive system, and as a receptor antagonist, ketamine mitigates this. Intravenous (IV) ketamine has demonstrated efficacy in reducing post-operative, chronic, and cancer-related pain in pediatrics, as well as in reducing time to pain control in the emergency department (ED) in adults. Limited studies suggest efficacy in adult opioid-refractory SCD patients. This study is investigating the safety and tolerability of adjuvant low-dose IV ketamine bolus for pediatric SCD VOE in the ED, as well as its efficacy in improving pain control and reducing hospitalization.

  • Sickle Cell Disease
  • Vaso-Occlusive Crisis

Total execution time in seconds: 0.4155650138855